Novartis AG
Close on Nov 2, 2026Market cap $308.20BP/E 22.6Yield –
Novartis Cosentyx (secukinumab by Year
Cosentyx (secukinumab — psoriasis, psoriatic arthritis, ankylosing spondylitis & HS) ($M)
Novartis Cosentyx (secukinumab: $6,668M in FY2025, up 8.6% from a year earlier. That is the highest of the 9 years on record here.
Where the FY2025 figure comes from
“|| Cosentyx | 6 668 | 6 141 | 9 | 8”
Source: Novartis Form 6-K (0001114448-26-000007) ↗
Reported in Form 6-K & Form 20-F.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Cosentyx (secukinumab — psoriasis, psoriatic arthritis, ankylosing spondylitis & HS) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 6,668 | +8.6% | Novartis Form 6-K (0001114448-26-000007) ↗ |
| FY2024 | Dec 31, 2024 | 6,141 | +23.3% | Novartis Form 6-K (0001114448-26-000007) ↗ |
| FY2023 | Dec 31, 2023 | 4,980 | +4.0% | Novartis Form 6-K (0001370368-25-000007) ↗ |
| FY2022 | Dec 31, 2022 | 4,788 | +1.5% | Novartis Form 6-K (0001370368-24-000007) ↗ |
| FY2021 | Dec 31, 2021 | 4,718 | +18.1% | Novartis Form 6-K (0001370368-23-000008) ↗ |
| FY2020 | Dec 31, 2020 | 3,995 | +12.5% | Novartis Form 6-K (0001370368-22-000009) ↗ |
| FY2019 | Dec 31, 2019 | 3,551 | +25.2% | Novartis Form 6-K (0001370368-21-000008) ↗ |
| FY2018 | Dec 31, 2018 | 2,837 | +37.0% | Novartis Form 6-K (0001370368-20-000007) ↗ |
| FY2017 | Dec 31, 2017 | 2,071 | – | Novartis Form 6-K (0001370368-19-000006) ↗ |
Breakdown
What makes up cosentyx (secukinumab
Cite this data
StockData. (2026). Novartis Cosentyx (secukinumab ($M), annual FY2017–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-cosentyx
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.